Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in Australia
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction Protonitazene is an opioid belonging to the 2-benzylbenzimidazole structural class. We describe two cases of opioid toxicity involving the reported inhalation of a delta-9-tetrahydrocannabinol vape product in which protonitazene was detected.Case reports Case 1 was a young male found unconscious after the reported use of a delta-9-tetrahydrocannabinol vape. He suffered two subsequent apnoeic episodes requiring bag-valve-mask ventilation before eventual recovery. Only protonitazene was detected in blood at a concentration of 0.74 µg/L. Case 2 was a young male who died shortly after being found unresponsive. The postmortem femoral blood concentrations of protonitazene and delta-9-tetrahydrocannabinol were 0.33 µg/L and 2 µg/L, respectively. Analysis of a pod vaping device found in the decedent’s hand and a separate e-liquid bottle labelled as delta-9-tetrahydrocannabinol showed a mixture of protonitazene and delta-9-tetrahydrocannabinol.Discussion The opioid effects of protonitazene are mediated through β-arrestin2 and mu opioid receptor signalling pathways. Benzimidazole opioids are lipophilic and, when mixed with a suitable solvent, can be used in a vape device. It is anticipated that naloxone would have provided effective reversal of toxicity in our cases.Conclusions Novel routes of opioid administration, like vaping, may appear relatively innocuous in comparison to intravenous administration, but opioids may still be absorbed at high concentrations, resulting in severe opioid toxicity or death.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical management requires opioid reversal with naloxone which has shown to improve mental status and reverse sedation in multiple exposure cases [30, 31].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [31]
In the citing paper
“Fatal outcomes have also been reported, including death and brain death, which demonstrates the high level of lethality of these drugs [21, 30, 31].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [31]
In the citing paper
“Severe toxicity has also been linked to vaping associated use of nitazene [21, 31].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [31]
In the citing paper
“Across different case reports, nitazene toxicity is characterized by apneic episodes and hypoventilation, including respiratory compromise requiring manual ventilation [29–31].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [31]
Citations
Cites
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141
Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161116 · Cited by 103
Schumann, J. L., Syrjanen, R., Alford, K., Mashetty, S., Castle, J. W., Rotella, J., Maplesden, J., & Greene, S. L. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac062 · Cited by 61
Self-citationPapsun, D. M., Krotulski, A. J., & Logan, B. K. (2022) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000787 · Cited by 51
Walton, S. E., Krotulski, A. J., Glatfelter, G. C., Walther, D., Logan, B. K., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06292-5 · Cited by 33
Acute metonitazene poisoning reversed by naloxone
White, A., Seah, V., Brown, J., McDonald, C., Tran, J., & Roberts, D. M. (2023) · Clinical Toxicology · doi:10.1080/15563650.2022.2164505 · Cited by 12
Research works printed but not linked: 1
- The World Health Organisation. Critical review report: protonitazene. Expert Committee on Drug Dependence. Geneva, Switzerland: The World Health Organisation; 2022. p. 16.
Cited by
Vandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 36
Isoardi, K. Z., Alfred, S., Weber, C., Harris, K., Soderstrom, J., Syrjanen, R., Thompson, A., Schumann, J., Stockham, P., Sakrajda, P., et al. (2026) · Drug and Alcohol Review · doi:10.1111/dar.13998 · Cited by 26
Self-citationClinical Experiences With the Nitazene Class of Synthetic Opioids: A Cohort Study
Roberts, D. M., Tisdell, B., Sajeev, M. F., Jiranantakan, T., Harvey, C., & Brown, J. A. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.06.619 · Cited by 20
Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.-H., Ledochowski, S., Labat, L., Mégarbane, B., & Houzé, P. (2025) · Metabolites · doi:10.3390/metabo15060371 · Cited by 14
Trends in novel opioid use and detections in exposures and police drug seizures in New South Wales
Smith, J. L., Brown, J. A., Atefi, D., Jiranantakan, T., Shaw, V., Ewers, C., du Toit‐Prinsloo, L., & Roberts, D. M. (2025) · Drug and Alcohol Review · doi:10.1111/dar.14057 · Cited by 12
“Other peer-reviewed published reports on nitazene poisonings in Australia include two from Victoria and one from NSW [10 – 12].”
Metadata
- Authors
- Syrjanen, R., Schumann, J. L., Castle, J. W., Sharp, L., Griffiths, A., Blakey, K., Dutch, M., Maplesden, J., & Greene, S. L.
- Affiliations
- Austin Hospital (AU)
- Victorian Institute of Forensic Medicine (AU)
- Forensic Toxicology, Forensic and Scientific Services, Coopers Plains, Australia
- Forensic Chemistry, Forensic Science Queensland, Coopers Plains, Australia
- The University of Melbourne (AU)
- St Vincent's Hospital Melbourne (AU)
- Corresponding author
- Greene, Shaun L.
- ORCID
- Venue
- Clinical Toxicology
- Publisher
- Informa UK Limited
- Published
- 2024-07-30
- Volume
- 62
- Issue
- 8
- Pages
- 539-541
- ISSN
- 0009-9309 (ISSN-L)
- 1556-3650
- 1556-9519
- OpenAlex
- W4401121511
- Cited by
- 19
- References
- 7
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 1
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Victorian Department of Health
- the National Health and Medical Research Council (GNT2001107)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- opioid toxicity, vaping, delta-9-tetrahydrocannabinol, β-arrestin2, mu-opioid receptor, naloxone, postmortem toxicology, apnea
- MeSH terms
- Vaping, Adult, Analgesics, Opioid, Australia, Benzimidazoles, Humans, Indazoles, Male, Dronabinol, Valine, Fatal Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in Australia. https://app.cochat.ai/papers/10.1080/15563650.2024.2383692
- The paper
- Syrjanen, R., Schumann, J. L., Castle, J. W., Sharp, L., Griffiths, A., Blakey, K., Dutch, M., Maplesden, J., & Greene, S. L. (2024). Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in Australia. Clinical Toxicology. https://doi.org/10.1080/15563650.2024.2383692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.